Literature DB >> 11845883

Repair of congenital malformations of the mitral valve: early and midterm results.

Edvin Prifti1, Vittorio Vanini, Massimo Bonacchi, Giacomo Frati, Massimo Bernabei, Gabriele Giunti, Adrian Crucean, Stefano Vincenzo Luisi, Bruno Murzi.   

Abstract

BACKGROUND: The aims of this study were to determine early and midterm survival and freedom from reoperation, and to identify the predictors for poor postoperative outcome in children undergoing mitral valve (MV) repair owing to congenital malformations of the mitral valve.
METHODS: Between January 1990 and February 2001, 94 consecutive children with congenital MV disease underwent valve repair. The mean age was 5.2+/-3.3 years (range 20 days to 15 years). Twenty-five (26.6%) children were less than 1 year old. Isolated MV disease was found in 21 (22.4%) patients. MV stenosis was the predominant lesion in 21 (22.4%) patients with a mean left atrial to left ventricle diastolic peak gradient of 24.5+/-9.2 mm Hg. MV regurgitation was the predominant pathophysiology in 73 (77.6%) patients with a mean regurgitation grade of 3.3+/-0.7.
RESULTS: The hospital mortality was 8.5% (8 of 94). Three patients required permanent pacemaker implantation owing to complete atrioventricular block. Two patients underwent mediastinal exploration for significant bleeding. Postoperatively the echocardiography color Doppler study demonstrated a significantly lower mean end diastolic left atrium to left ventricle gradient 8.7+/-2.2 mm Hg (p < 0.001) in patients with MV stenosis and a mean regurgitation grade of 0.9+/-0.6 (p < 0.001) in patients with MV regurgitation. Actuarial survival and actuarial reoperation-free survival were 89.2% and 76.3%, respectively. Multivariate analysis demonstrated that age less than 1 year (p = 0.035), hammock MV (p = 0.0093), cardiothoracic ratio greater than 0.6 (p < 0.0001), and associated cardiac anomalies (p = 0.003) were strong predictors for poor overall freedom from reoperation and midterm survival.
CONCLUSIONS: Mitral valve repair for congenital mitral valve disease yields acceptable early and midterm mortality and reoperation rates. Strong predictors for poor overall freedom from reoperation and midterm survival were age less than 1 year, hammock MV, cardiothoracic ratio greater than 0.6, and associated cardiac anomalies.

Entities:  

Mesh:

Year:  2002        PMID: 11845883     DOI: 10.1016/s0003-4975(01)03419-1

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Hammock mitral valve in an adult patient.

Authors:  Takayoshi Kato; Shinji Tomita; Mototsugu Tamaki; Yasuhide Okawa; Hitoshi Matsuo; Ryu-Hei Tanaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-01-13

Review 2.  Paediatric mitral valve disease - from presentation to management.

Authors:  Roshan Ganeshan; Hussain Imtiaz Shah; Sashini Iddawela; Prince Josiah Sajanthan Joseph; Temitope Adebowale Temidayo Olatigbe; Anawinla Ta Anyu; Khaled Hadi; Abdulla Tarmahomed; Amer Harky
Journal:  Eur J Pediatr       Date:  2021-07-26       Impact factor: 3.183

3.  Congenital mitral valve lesions : Correlation between morphology and imaging.

Authors:  Bo Remenyi; Tom L Gentles
Journal:  Ann Pediatr Cardiol       Date:  2012-01

4.  A Rare Encounter of Mitral Arcade With Anomalous Papillary Muscles.

Authors:  Ranbir Singh; Maureen Wang
Journal:  Cureus       Date:  2022-01-14

5.  Idiopathic isolated annular dilatation causing congenital mitral regurgitation.

Authors:  Lalitaditya Malik; Anubhav Gupta; Ranjit Kumar Nath; Vijay Grover; Vijay Kumar Gupta
Journal:  Ann Pediatr Cardiol       Date:  2012-07

6.  Early and Mid-Term Outcome of Pediatric Congenital Mitral Valve Surgery.

Authors:  Ramin Baghaei; Avisa Tabib; Farshad Jalili; Ziae Totonchi; Mohammad Mahdavi; Behshid Ghadrdoost
Journal:  Res Cardiovasc Med       Date:  2015-08-01

7.  Repair of anomalous mitral arcade in a child.

Authors:  Siddharthan Deepti; Velayoudam Devagourou; Shyam Sunder Kothari
Journal:  Ann Pediatr Cardiol       Date:  2017 May-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.